Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients
Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients
复制标题
DOI：
10.1080/22221751.2020.1756699
复制
发表时间：
2020-01-01
影响因子：
13.2
通讯作者：
Bing Gu
中科院分区：
文献类型：
--
作者：
Zhang Yongchen;Han Shen;Bing Gu
有效缓解2019年新型冠状病毒（COVID-19）持续大流行的策略需要全面了解针对严重急性呼吸道综合征冠状病毒2（SARS-CoV-2）的体液反应，SARS-CoV-2是引起COVID-19的新病毒。开始报告COVID-19患者中病毒复制和脱落的动态特征沿着病毒抗原特异性抗体应答，但对其模式尚未达成共识。在此，我们对江苏省两个医疗中心的21名SARS-CoV-2感染者进行了系列调查，其中包括11名非重症COVID-19患者，5名重症COVID-19患者和5名无症状携带者，根据核酸检测和临床症状。从这些人中采集纵向拭子样本和血清，分别用于病毒RNA检测和抗体应答。我们的数据显示，这些群体之间的血清转换的不同模式。所有11名非重症COVID-19患者和5名重症COVID-19患者在住院或随访期间均发生血清转化，表明血清学检测是对有症状COVID-19患者核酸检测的补充检测。值得注意的是，与非重度病例相比，在重度病例中发现了即时抗体应答。另一方面，无症状携带者中只有1例发生血清转化。在观察期间，SARS-CoV-2特异性抗体应答保持良好。这些信息具有直接相关性，将有助于COVID-19的临床诊断、预后和疫苗设计。
Effective strategy to mitigate the ongoing pandemic of 2019 novel coronavirus (COVID-19) require a comprehensive understanding of humoral responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the emerging virus causing COVID-19. The dynamic profile of viral replication and shedding along with viral antigen specific antibody responses among COVID-19 patients started to be reported but there is no consensus on their patterns. Here, we conducted a serial investigation on 21 individuals infected with SARS-CoV-2 in two medical centres from Jiangsu Province, including 11 non-severe COVID-19 patients, and 5 severe COVID-19 patients and 5 asymptomatic carriers based on nucleic acid test and clinical symptoms. The longitudinal swab samples and sera were collected from these people for viral RNA testing and antibody responses, respectively. Our data revealed different pattern of seroconversion among these groups. All 11 non-severe COVID-19 patients and 5 severe COVID-19 patients were seroconverted during hospitalization or follow-up period, suggesting that serological testing is a complementary assay to nucleic acid test for those symptomatic COVID-19 patients. Of note, immediate antibody responses were identified among severe cases, compared to non-severe cases. On the other hand, only one were seroconverted for asymptomatic carriers. The SARS-CoV-2 specific antibody responses were well-maintained during the observation period. Such information is of immediate relevance and would assist COVID-19 clinical diagnosis, prognosis and vaccine design.